Duration of diabetes as an important risk factor of microalbuminuria in type 2 diabetes
Article Sidebar
Main Article Content
Abstract
Microalbuminuria is the earliest evidence of diabetic nephropathy and a major predictor of end stage renal disease (ESRD). The objective of the study was to determine the influence of several risk factors on the presence of microalbuminuria in type 2 diabetics.
METHODS
This observational cross-sectional study was done on 73 patients with type 2 diabetes, who attended the Prolanis program in Primary Health Care from May to November 2018. Detailed medical histories including duration of diabetes and relevant clinical examinations including fasting blood sugar (FBS), post-prandial blood sugar (PPBS), HbA1c, serum creatinine, blood urea and urinary microalbumin were recorded for each patient. A multiple regression analysis was used to analyze the data. The analysis was assessed at 5% level of significance.
RESULTS
Mean age of study population was 51.89 ± 6.78 years with female preponderance (51.1%). Mean FBS, PPBS, HbA1c, duration of diabetes, systolic blood pressure, microalbuminuria and serum creatinine was 182.51 ± 74.63 mg/dL, 186.25 ± 26.72 mg/dL, 8.8 ± 1.83%, 9.37 ± 5.96 years, 118.44 ± 4.13 mmHg, 30.32 ± 3.2 mg/day and 1.33 ± 0.64 mg/dL respectively. Duration of diabetes and HbA1c were positively correlated with microalbuminuria (â=0.052; Beta =0.367; p<0.001 and â=0.058; Beta=0.363; p<0.001) respectively.
CONCLUSIONS
Duration of diabetes was the most important risk factor of microalbuminuria in type 2 diabetes patients. Therefore microalbuminuria can predict diabetic nephropathy earlier, as a warning to prevent further worsening of diabetic complications.
Article Details
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
References
Kumar R, Abbas A, Fausto N, Aster JC, eds. Robbins and Cotron Pathologic basis of disease. 8th ed. Philadelphia: Saunders Elsevier Publishing Division; 2010.
Lee JM, Eason A, Nelson C, et al. Screening practices for identifying type 2 diabetes in adolescents. J Adolesc Health 2014;54:139–43.
Liu Z, Fu C, Wang W, Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes 2010;8:62. doi: 10.1186/ 1477-7525-8-62.
Jun M, Perkovic V, Cass A. Intensive glycemic control and renal outcome. Contrib Nephrol 2011;170:196–208. doi: 10.1159/000325664.
Haller H, Ito S, Izzo Jr JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907–17. doi: 10.1056/NEJMoa1007994.
Chen WZ, Hung CC, Wen YW, Ning HC, Gau BR, Huang YY. Effect of glycemic control on microalbuminuria development among type 2 diabetes with high-normal albuminuria. Ren Fail 2014; 36: 171–5. DOI: 10.3109/0886022X. 2013.832312.
Murussi M, Campagnolo N, Beck MO, Gross JL, Silveiro SP. High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian type 2 diabetic patients: an 8-year follow-up study. Diabet Med 2007;24:1136–42
Hsu CC, Chang HY, Huang MC, et al. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. Diabetologia 2012; 55:3163–72. DOI 10.1007/s00125-012-2700-4.
Hsu CC, Chang HY, Huang MC, et al. Association between insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective cohort study. Diabetes Care. 2011;34:982–7. doi: 10.2337/dc10-1718.
Gupta M, Singh JP. Correlation of microalbuminuria with glycosylated haemoglobin in patients of diabetes having nephropathy. Int J Adv Med 2017;4:805-8. DOI: http://dx.doi.org/10.18203/2349-3933. ijam20172276.
Thakur SK, Dhakal SP, Parajuli S, Sah AK, Nepal SP, Paudel BD. Microalbuminuria and its risk factors in type 2 diabetic patients. J Nepal Health Res Counc 2019;17:61-5. doi: 10.33314/ jnhrc.1620.
Ansar MM, Shahrokhirad R, Lebady MK. Risk factors of microalbuminuria and macroalbuminuria in type 2 diabetic patients in North of Iran – Rasht. Nephrourol Mon 2017; 9:e40031.doi: 10.5812/numonthly.40031.
Pasko N, Toti F, Strakosha A, et al. Prevalence of microalbuminuria and risk factor analysis in type 2 diabetes patients in Albania: the need for accurate and early diagnosis of diabetic nephropathy. Hippokratia 2013;17: 337-41.
Parchwani DN, Upadhyah AA. Diabetic nephropathy: progression and pathophysiology. Int J Med Sci Public Health 2012; 4: 7-11. DOI: 10.5455/ijmsph.2012.1.59-70.
Dadhania BP, Aravat AH, Dhruva GA. Study of microalbuminuria in type 2 diabetes patients as a marker of morbidity (a study of 100 cases in Rajkot City). JBAR 2012;3:763-6.
Kundu D, Roy A, Mandal T, Bandyopadhyay U, Ghosh E, Ray D. Relation of microalbuminuria to glycosylated hemoglobin and duration of type 2 diabetes. Niger J Clin Pract 2013;16:216-20.
Baig JA, Asif N, Sarfaraz A, Alam JM. Correlation of microalbuminuria with glycosylated hemoglobin (Hba1c) and duration of type 2 diabetes mellitus (T2DM) in male and female patients. Middle-East J Sci Res. 2016; 24:2900-3.
Bagzai A, Bagzai DS. Correlation between severity of microalbuminuria with HbA1c in type II diabetic patients. JMSCR2019;7:310-3.
Sabatini S, Kurtzman NA. Role of hyperfiltration in the pathogenesis of diabetic nephropathy. In: Advances in pathogenesis of diabetic nephropathy. New York: Nova Science Publishers, Inc; 2012.p.:1-27.
Kondaveeti SB, Kumaraswamy D, Mishra S, Kumar AR, Shaker IA, Evaluation of glycated albumin and microalbuminuria as early risk markers of nephropathy in type 2 diabetes mellitus. J Clin Diagn Res 2013;7: 1280–3. doi: 10.7860/JCDR/2013/5145.3117.